ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022
Vision Defense: Efficient Antibacterial AIEgens Induced Early Immune Response for Bacterial Endophthalmitis.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 49 citations in OpenAlex.
- Next-generation smart ophthalmic biomaterials: From passive response to active interaction and closed-loop control.Bioactive materials · 2026Review
- A Tailored Artificial Biocatalyst for Bacterial Endophthalmitis Therapy via Enhanced Ferroptosis-Like Death.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The pathogenesis, risk factors, diagnosis and treatment of Acanthamoeba keratitis.Frontiers in medicine · 2025Review
- Sulfur oxidation states manipulate excited state electronic configurations for constructing highly efficient organic type I photosensitizers.Chemical science · 2024Article
- Theranostic Fluorescent Probes.Chemical reviews · 2024Review
- Transformable nano-antibiotics for mechanotherapy and immune activation against drug-resistant Gram-negative bacteria.Science advances · 2023Article
- Oxidization enhances type I ROS generation of AIE-active zwitterionic photosensitizers for photodynamic killing of drug-resistant bacteria.Chemical science · 2023Article
- Vision Defense: Efficient Antibacterial AIEgens Induced Early Immune Response for Bacterial Endophthalmitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Efficient antibacterial AIEgens induced ROS for selective photodynamic treatment of bacterial keratitis.Frontiers in chemistry · 2022Article
- Nanopore techniques as a potent tool in the diagnosis and treatment of endophthalmitis: a literature review.International journal of ophthalmology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Bacterial endophthalmitis (BE) is an acute eye infection and potentially irreversible blinding ocular disease. The empirical intravitreous injection of antibiotic is the primary treatment once diagnosed as BE. However, the overuse of antibiotic contributes to the drug resistance of pathogens and the retinal toxicity of antibiotic limits its application in clinic. Herein, a cationic aggregation-induced emission luminogens named with triphenylamine thiophen pyridinium (TTPy) is reported for photodynamic treatment of BE. TTPy can selectively discriminate and kill bacteria efficiently over normal ocular cells. More importantly, TTPy shows excellent antibacterial ability in BE rat models infected by Staphylococcus aureus. Meanwhile, the bacterial killing behavior triggered by TTPy induces innate immune response at an early stage of infection, limiting subsequent robust inflammation and protecting retina from bacterial toxins and inflammation-induced bystander damage. In addition, TTPy performs better antibacterial ability than commercially used Rose Bengal, suggesting its excellent capability of vision salvage in acute BE. This study exhibits an efficient photodynamic antibacterial treatment to BE, which induces an early intraocular immune response and saves useful vision, endowing TTPy a promising potential for clinical application of ocular infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.